Want to see HYPR full AI Analyst Report?
Top Page
Hyperfine
(NASDAQ:HYPR)
Select Model
Select Model
Rating:49Neutral
Price Target:
$0.83
▼(-4.71% Downside)
Action:Reiterated
Date:08/07/26
HYPR scores below average primarily due to heavy ongoing losses and negative free cash flow despite improving gross margins and low leverage. Technical signals are also weak with the stock trading below key moving averages and negative MACD. Offsetting these risks, the latest earnings call was relatively constructive with reiterated high-growth revenue guidance, sustained >50% gross margins, and improving (but still negative) cash burn and runway into 2028.
Positive Factors
Strong revenue and unit growth
Rapid revenue and placement growth indicates increasing customer adoption of portable MRI. Continued Model 2 sales, hospital conversions, office expansion and international rollout could expand the installed base and support recurring service revenue over the medium term.
Negative Factors
Deep and persistent operating losses
The company remains far from profitability despite revenue growth and better gross margins. Operating costs still substantially exceed the current revenue base, creating dependence on continued funding and successful execution before the business can become self-sustaining.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue and unit growth
Rapid revenue and placement growth indicates increasing customer adoption of portable MRI. Continued Model 2 sales, hospital conversions, office expansion and international rollout could expand the installed base and support recurring service revenue over the medium term.
Read all positive factors
Hyperfine (HYPR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$85.97M
Dividend YieldN/A
Average Volume (3M)548.13K
Price to Earnings (P/E)―
Beta (1Y)1.19
Revenue Growth53.16%
EPS Growth27.17%
CountryUS
Employees102
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.38
Shares Outstanding90,993,380
10 Day Avg. Volume484,276
30 Day Avg. Volume548,131
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)2.25
Price to Sales (P/S)6.80
P/FCF Ratio-3.17
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.03Price Target Upside133.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$20.16M
Hyperfine Business Overview & Revenue Model
Company Description
Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength t...
How the Company Makes Money
Hyperfine primarily generates revenue by selling its portable MRI systems and related accessories to healthcare providers and research institutions. In addition to hardware sales, the company earns recurring revenue from service and support arrang...
Hyperfine Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational and commercial progress: double-digit revenue and unit growth, sustained gross margins above 50%, improved cash burn, strengthened balance sheet via ATM proceeds, meaningful clinical evidence (PRIME, NEURO PMR), regulatory approvals (CE/UKCA) and clear product roadmaps (contrast labeling, AI-enabled software). Notable challenges remain, including a sizable ongoing net loss, persistent (though improving) cash burn, modest absolute revenue and unit volume, timing sensitivity to IDN budget cycles, and pending regulatory label expansion for contrast. Management reiterated full-year guidance and emphasized identifiable growth drivers, suggesting confidence in conversion of recent momentum into scale.Positive Updates
Strong Revenue Growth
Q2 revenue of $3.9M, up ~45% year-over-year from $2.7M; first half revenue $7.8M, up ~62% year-over-year from $4.8M. Company reiterated full-year 2026 revenue guidance of $20M–$22M (midpoint ≈ 55% YoY growth).
Negative Updates
Continued Net Loss
Net loss of $9.3M in Q2 (loss per share $0.09) compared to $9.2M a year ago (loss per share $0.12). Loss included $0.6M non-cash loss from change in fair value of warrant liabilities.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Revenue Growth
Q2 revenue of $3.9M, up ~45% year-over-year from $2.7M; first half revenue $7.8M, up ~62% year-over-year from $4.8M. Company reiterated full-year 2026 revenue guidance of $20M–$22M (midpoint ≈ 55% YoY growth).
Read all positive updates
Company Guidance
Hyperfine reiterated full-year 2026 guidance of $20.0–$22.0 million in revenue (midpoint implying ~55% YoY growth), gross margin of 50–55% for the year, and total cash burn of $26–$28 million (≈10% YoY decline at the midpoint), and said its cash runway extends into 2028. Management pointed to supporting results in the first half—Q2 revenue $3.9M (up ~45% YoY) and H1 revenue $7.8M (up ~62% YoY), Q2 unit sales 12 (up 50% YoY) and H1 units 22 (up ~57% YoY), Q2 gross margin 50.7% (fourth consecutive quarter >50%, +150 bps YoY), and improving cash burn (Q2 net cash burn excl. financing $7.9M; H1 $16.6M, down ~9% YoY). As of June 30, 2026 the company had $43.5M cash, a $2.7M quarterly increase that included $10.6M of ATM proceeds at an average $1.52/share, and cited identifiable second-half drivers (Model 2 adoption, hospital/IDN conversions, office growth, international rollout, clinical/economic evidence, software and contrast labeling catalysts) supporting the guidance.Hyperfine Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.54M | 13.56M | 12.89M | 11.03M | 6.81M | 1.50M |
| Gross Profit | 8.50M | 6.75M | 5.89M | 4.76M | 907.00K | -1.17M |
| EBITDA | -32.43M | -33.37M | -39.71M | -43.18M | -72.15M | -64.13M |
| Net Income | -34.85M | -35.57M | -40.72M | -44.24M | -73.16M | -64.83M |
Balance Sheet | ||||||
| Total Assets | 63.00M | 55.26M | 58.90M | 94.20M | 134.05M | 202.47M |
| Cash, Cash Equivalents and Short-Term Investments | 43.46M | 35.09M | 37.65M | 75.18M | 118.24M | 188.50M |
| Total Debt | 13.41M | 314.00K | 269.00K | 185.00K | 0.00 | 0.00 |
| Total Liabilities | 26.24M | 14.26M | 9.86M | 9.80M | 10.33M | 16.25M |
| Stockholders Equity | 36.76M | 41.01M | 49.04M | 84.40M | 123.72M | 186.23M |
Cash Flow | ||||||
| Free Cash Flow | -27.53M | -29.13M | -39.15M | -42.61M | -72.92M | -49.89M |
| Operating Cash Flow | -27.07M | -27.95M | -38.77M | -41.81M | -72.34M | -47.18M |
| Investing Cash Flow | -465.00K | -1.19M | -383.00K | -804.00K | -585.00K | -2.71M |
| Financing Cash Flow | 46.72M | 27.50M | 1.02M | 174.00K | 7.00K | 176.77M |
Hyperfine Technical Analysis
Negative
0.87
Price Trends
1.02
Negative
1.25
Negative
1.18
Negative
Market Momentum
-0.06
Negative
26.08
Positive
8.27
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYPR, the sentiment is Negative. The current price of 0.87 is below the 20-day moving average (MA) of 0.89, below the 50-day MA of 1.02, and below the 200-day MA of 1.18, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 26.08 is Positive, neither overbought nor oversold. The STOCH value of 8.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HYPR.
Hyperfine Risk Analysis
Hyperfine disclosed 79 risk factors in its most recent earnings report. Hyperfine reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Hyperfine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $1.10B | 47.35 | 23.45% | 1.30% | 11.21% | 11.08% | |
62 Neutral | $2.22B | -26.26 | -38.36% | ― | 28.14% | -5.15% | |
56 Neutral | $943.33M | -14.10 | -44.85% | ― | 31.70% | -28.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $454.51M | -12.13 | -188.09% | ― | 25.86% | -47.31% | |
49 Neutral | $85.97M | -2.11 | -100.30% | ― | 53.16% | 27.17% | |
46 Neutral | $61.76M | -0.67 | -51.88% | ― | 25.74% | -26.25% |
* Healthcare Sector Average
HYPR
Hyperfine
0.81
-0.31
-28.04%
CLPT
ClearPoint Neuro
14.31
3.23
29.15%
IRMD
Iradimed
86.17
15.01
21.10%
BFLY
Butterfly Network
7.60
6.07
396.73%
NNOX
Nano-X Imaging
0.76
-2.96
-79.49%
CBLL
Ceribell, Inc.
24.81
12.48
101.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.